login
  Password reminder
Cardiac Rhythm News
Contact the editor Visit Cardiac Rhythm News Twitter feed Visit Cardiac Rhythm News Facebook page
 

Convergent procedure building support for interdisciplinary approach to atrial fibrillation


Tuesday, 05 Jun 2012 15:37
Borut Gersak
Borut Gersak


nContact has announced that an article was recently published in the Journal of Cardiovascular Electrophysiology chronicles the development of an new interdisciplinary approach for the treatment of atrial fibrillation, the convergent procedure, and illustrates the strong success of the site’s programme. Outcomes were determined by the most stringent methodology, 24-hour loop recorders, which demonstrated unparalleled success in this patient cohort. Physician reaction to the paper has been positive.


Lead author of the paper, Borut Gersak, chief of Cardiac Surgery, University Medical Center, Ljubljana, Slovenia, said: “This paper may be reviewed in hindsight as a pivotal paper in determining the true standard for success of an ablation procedure. The paper documents the evolution of a closed chest, truly minimally invasive interdisciplinary procedure, the Convergent Procedure, its early challenges and lessons learned, the protocols developed to improve and insure clinical safety, and the successful patient experience as monitored by a continuous loop recorder, Medtronic’s Reveal XT. The convergent procedure has proven itself under today’s most stringent monitoring standards, and sets a new and higher standard for clinical and patient outcome success.”

Kenneth Civello, cardiac electrophysiologist, Our Lady Of The Lake Regional Medical Center, Baton Rouge, Louisiana, USA, said: “The data is impressive, and the results are consistent with results we have obtained utilizing the Convergent Procedure in our hospital, and abstracts presented at Boston AF Symposium and the Heart Rhythm Society Scientific Sessions (HRS). This is important because the procedure can be standardised to obtain consistent results among a variety of sites. The results with patients in sinus rhythm off anti-arrhythmic drugs (AADs) of 74% are even more impressive because 94% of the patients were persistent or long standing persistent patients. HRS defines catheter outcome success as ’freedom from AF and off AADs at 40%’ for persistent patients and 30% for long standing persistent patients.”

Paul Mounsey, chief of Electrophysiology, University of North Carolina Hospital, Chapel Hill, North Carolina, USA, said: “This is an important paper because the Convergent Procedure addresses atrial fibrillation in a scientific manner by addressing both endocardial and epicardial substrates in a comprehensive anatomic approach. Its success can be related back to the large body of literature on lesion patterns, lesion completeness, substrate activation, anatomical remodeling, atrial stretch, and atrial function. This is not a potential magical silver bullet, but rather the use of an increasingly relevant and rapidly growing ablation technology to augment existing strategies.”

 




Add New Comment

Most popular


Thursday, 26 Feb 2015
Vitaria delivers autonomic regulation therapy for patients who have moderate to severe heart failure with left ventricular dysfunction (ejection fraction < 40%), and who remain symptomatic despite ... Vitaria vagal nerve stimulation system receives CE mark for treatment of chronic heart failure

Bridging during anticoagulation interruption associated with higher bleeding risk in AF patients
Friday, 30 Jan 2015
A subanalysis from the ORBIT-AF registry has found that atrial fibrillation patients who receive bridging anticoagulation therapy during anticoagulation interruption are at higher risk of bleeding ... Bridging during anticoagulation interruption associated with higher bleeding risk in AF patients

Sorin announces enrolment of first patients in the Vanguard clinical study
Thursday, 12 Feb 2015
The Vanguard (Vagal nerve stimulation safeguarding heart failure patients) clinical study evaluates Equilia, a neurostimulation system for heart failure patients. Sorin announces enrolment of first patients in the Vanguard clinical study

Features


SERVE-HF could be a wake-up call for cardiologists about central sleep apnoea
Tuesday, 24 Mar 2015
Martin Cowie (Imperial College London, London, UK) is the principal investigator of the SERVE-HF study, which is assessing the use of adaptive servo-ventilation (PaceWave, ResMed) in chronic heart ... SERVE-HF could be a wake-up call for cardiologists about central sleep apnoea

ENSURE-AF: Largest trial ever to explore novel oral anticoagulation in AF patients undergoing cardioversion
Tuesday, 10 Feb 2015
Andreas Goette explains the rationale and details of the ENSURE-AF trial, the largest prospective study evaluating the efficacy and safety of edoxaban (Daiichi Sankyo) compared with enoxaparin/... ENSURE-AF: Largest trial ever to explore novel oral anticoagulation in AF patients undergoing cardioversion

Profiles


Hung-Fat Tse
Tuesday, 03 Feb 2015
While Hung-Fat Tse’s initial research interests focused on device therapy for cardiac arrhythmias, ... Hung-Fat Tse

Massimo Santini
Friday, 10 Oct 2014
Massimo Santini performed the first fulguration of the atrioventricular node of resistant ... Massimo Santini

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions